Valo Health
Valo Health is a Boston-based AI drug discovery and development company incubated by Flagship Pioneering and launched in 2019.
About
Valo Health is a Boston-based AI drug discovery and development company incubated by Flagship Pioneering and launched in 2019. It combines large-scale human data, causal inference and machine learning in its end-to-end Opal computational platform to discover and develop therapeutics in cardiometabolic disease, oncology and neurodegeneration, advancing its own pipeline and partnering with pharma companies such as Novo Nordisk.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 11
Investor· 6
Founders / team· 2
Funding history
- 2021-01-11Series B$190M
Investors · Public Sector Pension Investment Board, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae AssetSource · valohealth.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Valo Health
Valo Health is a Boston-based AI drug discovery and development company incubated by Flagship Pioneering and launched in 2019.
Series B · $450M · 2021-01
$450M
United States
BusinessLatest roundTotal raisedDate- insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - DeepSeq.AI
AI design and optimization of biologics for large pharma, built on protein language models and large-scale wet-lab data
$620K
$620K
China
BusinessLatest roundTotal raisedDate- Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B - T-Therapeutics
T-Therapeutics is a 2022 University of Cambridge spin-out based in Cambridge, UK.
Series B · $224M · 2026-11
$224M - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M
Other / unspecified
BusinessLatest roundTotal raisedDate- Venomics AI
Venomics AI is a Bengaluru-based biotech spun out of the Indian Institute of Science that turns venom-derived peptides into drug candidates.
Pre-Seed · $3M · 2026-11
$3M - Miles Wang 新公司
Develops AI models for drug discovery
— - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 21 at a nearby stage · 32 in Boston Metro
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 21 at a nearby stage · 34 in Boston Metro
Request intro →Andreessen Horowitz
22 Life Sciences deals in the last 24 months · 13 at a nearby stage · 20 in Boston Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 11 at a nearby stage · 20 in Boston Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 12 at a nearby stage · 15 in Boston Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 10 at a nearby stage · 14 in Boston Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.